



MDR TB SUPPLEMENTAL SURVEILLANCE FORM

To be completed for all cases treated as MDR TB, regardless of DST results

DOH 343-233 November 2022

History of treatment before current episode with second-line TB drugs for the treatment of TB disease (not LTBI): ☐ Yes ☐ No ☐ Unknown								
TREATMENT COURSE								
Date MDR TB therapy started for current episo	/ Day / Year:	: 🔲						
Drugs ever used for MDR TB Treatment, from MDR start date: (Select one option for each drug)								
Drug			Length of time administered					
Isoniazid			□ Not Used □ < 1 month □ ≥1 month					
Rifampin		□ No	ot Used 🛚	< 1 mo	nth □ ≥1 month			
Pyrazinamide		□ No	ot Used 🗆	< 1 mo	nth □ ≥1 month			
Ethambutol		□ No	ot Used 🗆	< 1 mo	nth □ ≥1 month			
Streptomycin*		□ No	ot Used 🗆	< 1 mo	nth □ ≥1 month			
Rifabutin*		□ No	ot Used	< 1 mo	nth □ ≥1 month	<u> </u>		
Rifapentine*		□ No	ot Used 🗆	< 1 mo	nth □ ≥1 month			
Ethionamide*		□ No		< 1 mo				
Amikacin*		□ No	ot Used 🗆	< 1 mo	nth □ ≥1 month			
Kanamycin*		□ No		< 1 mo				
Capreomycin*				< 1 mo				
Ciprofloxacin*				< 1 mo				
Levofloxacin*				< 1 mo				
Ofloxacin*				< 1 mo				
Moxifloxacin*				< 1 mo				
Other Fluoroquinolones				< 1 mo				
Cycloserine*				< 1 mo				
Para-Amino Salicylic Acid*				< 1 mo				
Linezolid*		□ Not Used □ < 1 month □ ≥1 month						
Bedaquiline*				< 1 mo				
Delamanid*				< 1 mo				
Clofazimine*				< 1 mo				
Pretomanid*				< 1 mo				
Other (Specify:)				< 1 mo	nth □ ≥1 month			
*Indicates second- or third-line medication for purpose of US surveillance								
Date injectable medication was stopped: Month Day Year			Was surge ☐ Yes—	ry perfo	rmed to treat MDR			
□ Not Applicab					If YES, Date: M	onth Day Year	$\overline{}$	
				L	L			
Side effects								
Side effect	Experienced?				When?			
Depression	☐ Yes ☐	No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Suicide attempt or ideation	□ Yes □] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Cardiac abnormalities	□ Yes □] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Hearing loss	□ Yes □	No No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Tinnitus	☐ Yes ☐] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Vestibular dysfunction	☐ Yes ☐	No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Peripheral neuropathy	☐ Yes ☐] No	☐ Unknow	n 🔲 I	During Treatment	☐ At end of treatment	☐ Both	
Renal dysfunction	□ Yes □] No	☐ Unknow	n 🔲 I	During Treatment	☐ At end of treatment	☐ Both	
Vision change/loss	□ Yes □] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Liver toxicity	□ Yes □] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Myalgia	☐ Yes ☐] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Arthralgia	□ Yes □] No	☐ Unknow	n 🗆 I	During Treatment	☐ At end of treatment	☐ Both	
Other (Specify:	☐ Yes ☐	No	☐ Unknow	n 🗆 ı	During Treatment	☐ At end of treatment	□ Both	